Founded in 2007, Aqbiopharmais the first company specializing in the research and development of fluorine-containing new drugs and fluorine-containing pharmaceutical intermediates in China, and has created a new field of research and development of fluorine-containing new drugs and fluorine-containing pharmaceutical intermediates in China. The company has 2800 square meters of R & D and pilot base and 50 acres of industrialization base. After eight years of investment and development, more than 3,000 manufacturable products have been developed, of which 18 core process technologies and new drug research and development achievements have applied for invention patents. The company's main products include fluorine-containing pharmaceutical intermediates, piperidine, piperazine, pyrrolidine, azazindole, amantadine, azazo spiro, azazo ring。[View details]
The company has launched its new website
Congratulations on the successful project of "Shanghai Green Fluoropharmaceutical Engineering Technology Research Center" jointly established by Aqikang Medical Science and Technology and Shanghai University of Applied Technology!
Nucleic acid drugs are drugs that use the translation or regulation function of nucleic acid molecules to intervene in diseases. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs can intervene at the source, inhibit the expression of disease-related genes into pathological proteins, or introduce genes that can express normal proteins.